ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $800.27M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.07M
Average 1.91M
Returns on capital
ORIC Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.7%
avg -34.3%
ROIC
-36.3%
avg -44.1%
ROA
-31.5%
avg -39.1%
Analysis
ROA is currently the strongest return metric at -31.5% versus its period average of -39.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jacob Chacko | President, Chief Executive Officer & Director | USD 1.11M | 47 | 112.50K | 0.11% |
Pratik S. Multani | Chief Medical Officer | USD 774.94K | 59 | 35.50K | 0.03% |
Dominic G. Piscitelli | Chief Financial Officer | USD 729.92K | 51 | — | — |
Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board | USD 100K | 69 | 26.70K | 0.03% |
Scott W. Lowe | Founder & Member of Scientific Advisory Board | — | — | — | — |
Christian V. Kuhlen | General Counsel & Chief Compliance Officer | — | 53 | — | — |
Edna Chow Maneval | Executive Vice President of Clinical Development | — | 65 | — | — |
Kevin Brodbeck | Chief Technical Officer | — | — | — | — |
Daniel Iazzetti | Vice President & Head of People | — | — | — | — |
Charles L. Sawyers | Founder & Member of Scientific Advisory Board | — | 67 | — | — |
Lori Sickels Friedman | Chief Scientific Officer | — | 61 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$2.96M
Net Transaction Value
−$2.96M
Net selling
Most Active
Piscitelli Dominic
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 20, 26Oct 20, 2026 | Piscitelli Dominic Direct | Sell | $189.4K$189,390.60 |
| Oct 1, 26Oct 1, 2026 | Heyman Richard A. Direct | Sell | $45.2K$45,199.35 |
| Oct 1, 26Oct 1, 2026 | Heyman Richard A. Indirect | Sell | $41.3K$41,325.12 |
| Sep 28, 26Sep 28, 2026 | Piscitelli Dominic Direct | Sell | $181.3K$181,257.78 |
| Sep 24, 26Sep 24, 2026 | Piscitelli Dominic Direct | Sell | $1.4K$1,350.00 |
| Sep 24, 26Sep 24, 2026 | Piscitelli Dominic Direct | Sell | $6.8K$6,752.50 |
| Aug 26, 26Aug 26, 2026 | Piscitelli Dominic Direct | Sell | $1.1M$1,053,814.30 |
| Jul 24, 26Jul 24, 2026 | Heyman Richard A. Indirect | Sell | $73.3K$73,322.00 |
| Jul 24, 26Jul 24, 2026 | Heyman Richard A. Direct | Sell | $84.1K$84,140.00 |
| Jul 6, 26Jul 6, 2026 | Heyman Richard A. Indirect | Sell | $3.6K$3,600.00 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $2.96M over the last 12 months. That adds up to net selling of $2.96M. Piscitelli Dominic was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does ORIC Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ORIC's management, answered from reported figures.
Who manages ORIC?
ORIC Pharmaceuticals, Inc. (ORIC) lists 11 active executives. The top listed executive is Scott W. Lowe, Founder & Member of Scientific Advisory Board.
Are ORIC insiders buying or selling?
Recent insider activity shows net buying of $9.46M.
Continue the stock analysis
Jump to another research area for this company.